JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, J L
Right arrow Articles by Nagasaka, T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, J L
Right arrow Articles by Nagasaka, T
Journal of Clinical Pathology 2002;55:530-534
© 2002 Journal of Clinical Pathology


ORIGINAL ARTICLE

Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade

J L Xu1, R Lai3, T Kinoshita2, N Nakashima1, T Nagasaka1

1 Department of Laboratory Medicine, Nagoya University School of Medicine, Tsurumai-cho 65, Showa-ku Nagoya 466-8560, Japan
2 Department of Internal Medicine, Nagoya University School of Medicine
3 Department of Hematopathology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas TX77025, USA

Correspondence:
Dr T Nagasaka, Division of Pathology, Clinical Laboratory, Nagoya University Hospital, Tsurumai-cho 65, Showa-ku, Nagoya 466–8560, Japan;
nagat{at}med.nagoya-u.ac.jp Aims: Abnormalities involving proliferation, apoptosis, and angiogenesis are important in tumorigenesis. The purpose of this study was to examine these three biological processes, and their relation with the clinical stage and cytological grade in multiple myeloma (MM).

Methods: Fifty four newly diagnosed patients with MM were studied by immunohistochemistry using bone marrow clot sections. Proliferation and apoptosis were evaluated for the proportion of MM cells (indicated by morphology and CD138 reactivity) positive for the Ki67 antigen and single stranded DNA (ssDNA), respectively. Angiogenesis was evaluated by measuring the intratumoral microvessel density (IMVD) and by assessing the immunoreactivity of vascular endothelial growth factor (VEGF).

Results: There were 30 men and 24 women (median age, 65 years; range, 37–84). At initial presentation, 15 (28%) were in Durie stage I, 15 (28%) in stage II, and 24 (44%) in stage III. Advanced clinical stage correlated with high cytological grade (p < 0.03). The medians for Ki67, ssDNA, and IMVD were 4.4% (range, 0–15%), 0.2% (range, 0–2.8%), and 15.5 (range, 0–63), respectively. Among these three continuous parameters, the only significant correlation was that between Ki67 and IMVD (p < 0.0001). Both Ki67 and IMVD also correlated with the clinical stage, cytological grade, and VEGF positivity (p <0.05). No correlation was found between ssDNA and all of the other parameters.

Conclusions: These data suggest that proliferation is associated with angiogenesis in MM. Furthermore, proliferation and angiogenesis, but not apoptosis, may be important in disease progression. Lastly, increased production of VEGF may be one of the contributing factors to the increase in intratumoral vascularity seen in advanced MM.


Keywords: multiple myeloma; proliferation; apoptosis; angiogenesis; clinical stage; cytological grade

Abbreviations: IL, interleukin; IMVD, intratumoral microvessel density; MM, multiple myeloma; ssDNA, single stranded DNA; VEGF, vascular endothelial growth factor




This article has been cited by other articles:


Home page
BloodHome page
S. Colla, S. Tagliaferri, F. Morandi, P. Lunghi, G. Donofrio, D. Martorana, C. Mancini, M. Lazzaretti, L. Mazzera, L. Ravanetti, et al.
The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 {alpha} (HIF-1{alpha}) activity: involvement in myeloma-induced angiogenesis
Blood, December 15, 2007; 110(13): 4464 - 4475.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. Xu, K. Nagata, K. Obata, S. Ichihara, H. Izawa, A. Noda, T. Nagasaka, M. Iwase, T. Naoe, T. Murohara, et al.
Nicorandil Promotes Myocardial Capillary and Arteriolar Growth in the Failing Heart of Dahl Salt-Sensitive Hypertensive Rats
Hypertension, October 1, 2005; 46(4): 719 - 724.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
E. Van Valckenborgh, P. I. Croucher, H. De Raeve, C. Carron, E. De Leenheer, S. Blacher, L. Devy, A. Noel, E. De Bruyne, K. Asosingh, et al.
Multifunctional Role of Matrix Metalloproteinases in Multiple Myeloma: A Study in the 5T2MM Mouse Model
Am. J. Pathol., September 1, 2004; 165(3): 869 - 878.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson
Advances in biology of multiple myeloma: clinical applications
Blood, August 1, 2004; 104(3): 607 - 618.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Asosingh, H. De Raeve, E. Menu, I. Van Riet, E. Van Marck, B. Van Camp, and K. Vanderkerken
Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity
Blood, April 15, 2004; 103(8): 3131 - 3137.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Zangari, E. Anaissie, A. Stopeck, A. Morimoto, N. Tan, J. Lancet, M. Cooper, A. Hannah, G. Garcia-Manero, S. Faderl, et al.
Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma
Clin. Cancer Res., January 1, 2004; 10(1): 88 - 95.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. A. London, A. L. Hannah, R. Zadovoskaya, M. B. Chien, C. Kollias-Baker, M. Rosenberg, S. Downing, G. Post, J. Boucher, N. Shenoy, et al.
Phase I Dose-Escalating Study of SU11654, a Small Molecule Receptor Tyrosine Kinase Inhibitor, in Dogs with Spontaneous Malignancies
Clin. Cancer Res., July 1, 2003; 9(7): 2755 - 2768.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2002 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.